{"ticker": {"uuid": "109214f7-428e-4c03-be34-e28610c14d71", "symbol": "LRMR", "name": "Larimar Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy", "summary": "Larimar Therapeutics (LRMR) has submitted the initial module of its Biologics License Application (BLA) to the U.S. FDA for accelerated approval of its Nomlabofusp therapy, targeting Friedreich's ataxia. The therapy showed positive results in an open-label study, and the FDA conf", "url": "https://finance.yahoo.com/healthcare/articles/larimar-therapeutics-lrmr-submits-initial-154308058.html", "source_name": "Market source", "published_at": "2026-07-15T10:43:00", "published_display": "15 Jul 2026 10:43", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR | FinancialContent", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) on behalf of investors. The investigation stems from two instances where the company's stock price fell significantly after announcing \"positive\" data from a Friedre", "url": "https://www.financialcontent.com/article/gnwcq-2026-7-14-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-larimar-therapeutics-inc-lrmr", "source_name": "FinancialContent", "published_at": "2026-07-14T21:15:25", "published_display": "14 Jul 2026 21:15", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Larimar Therapeutics\u2019 Stock Surge Over 30% Pre-Market Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQQmU4N2hWTlEwb1lUSHJfeXlnOFlDbkRyWUNyZWxPT29QX3Z0NUl0eTE4UGJTZGEtM3U5dEhYeGNNRFVwMHROZm1CdzhVenJlRDA1OFNnTHozaThIWVZ1ejlsQzdLOUhHSXpiT2VCR1FDM2d0VDZLd0c3WjZRcDM0RGgwVGhkNWczem9Fb2F4N1Z6bmh3Tjc3a1Qtd1A5MEk3R21YMWxocmdLR2FSdEpRelZpRzEyREhTNUNTVVpR?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T03:50:05+00:00", "published_display": "14 Jul 2026 03:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Larimar Therapeutics, Inc. \u2013 LS:A2P5PP", "summary": "This article displays the \"Price to earnings forward\" for Larimar Therapeutics, Inc. (A2P5PP) on the TradingView platform. It shows that the market for this stock is closed and there have been no trades for this specific financial metric. The content primarily focuses on the disp", "url": "https://www.tradingview.com/symbols/LS-A2P5PP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T01:10:54", "published_display": "14 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy", "summary": "Larimar Therapeutics Inc. (LRMR) has priced an upsized $100 million stock offering after its shares surged over 60% following the FDA granting Breakthrough Therapy Designation to its frataxin protein replacement therapy, Nomlabofusp, for Friedreich\u2019s ataxia. The funds will suppor", "url": "https://stocktwits.com/news-articles/markets/equity/larimar-prices-100-m-stock-sale-after-record-rally-fueled-by-fda-breakthrough-tag-for-protein-replacement-therapy/cZR6UicRIbc", "source_name": "Stocktwits", "published_at": "2026-07-13T19:42:05", "published_display": "13 Jul 2026 19:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of Larimar Therapeutics, Inc. \u2013 NASDAQ:LRMR", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNcUU0UDY1RVRKd0lydnd2bGQ0OHl4amhBWkRZRDhPWHc0V0wzbHR5WnRhNDZucGNTS2pDVnNxU2s3bzByM0paQV93dUtJUE12V3otN19TQjQ2eFB0cEpQNXlKck9jNmtFMHF4bzdFTFI0YWhqNXg0ZkNENlpYNnhiU0tmZUcyTmpTb1dKQ1lBc25NbDVWRi11ZXl0Z21VZw?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T15:47:04+00:00", "published_display": "12 Jul 2026 15:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Thomas Hamilton Bought 6.1% More Shares In Larimar Therapeutics", "summary": "The article reports that Thomas Hamilton increased his holdings in Larimar Therapeutics by 6.1%. This acquisition suggests a positive outlook on the company's future prospects from a notable investor.", "url": "https://www.moomoo.com/news/post/72780626/thomas-hamilton-bought-6-1-more-shares-in-larimar-therapeutics", "source_name": "Moomoo", "published_at": "2026-07-10T18:09:42", "published_display": "10 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR", "summary": "Pomerantz LLP is investigating claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows two significant stock price drops after the company disclosed instances of anap", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-larimar-therapeutics-inc---lrmr-302822376.html", "source_name": "PR Newswire", "published_at": "2026-07-09T19:57:00", "published_display": "09 Jul 2026 19:57", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics stock jumps on insider purchase By Investing.com", "summary": "Larimar Therapeutics Inc (NASDAQ:LRMR) shares jumped 15.5% after director Thomas Edward Hamilton purchased 50,000 shares of common stock. The insider acquisition, valued at approximately $166,890, signals confidence in the biopharmaceutical company from a board member. Hamilton n", "url": "https://in.investing.com/news/stock-market-news/larimar-therapeutics-stock-jumps-on-insider-purchase-93CH-5490015", "source_name": "Investing.com India", "published_at": "2026-07-09T16:10:21", "published_display": "09 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Larimar Therapeutics, Inc. \u2013 SWB:ZA71", "summary": "This article provides financial information for Larimar Therapeutics, Inc. (SWB:ZA71) available on TradingView, specifically focusing on its enterprise value to revenue forward. It indicates the stock is traded on the Stuttgart Stock Exchange and details various financial and res", "url": "https://www.tradingview.com/symbols/SWB-ZA71/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T23:41:16", "published_display": "08 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000", "summary": "Shares of Larimar Therapeutics, Inc. (LRMR) rose 3% after hours following director Thomas E. Hamilton's purchase of 50,000 shares for approximately $167,000. This insider buying comes as H.C. Wainwright initiated 'Buy' coverage with a $10 price target, anticipating a commercial l", "url": "https://finance.yahoo.com/markets/stocks/articles/lrmr-stock-edges-hours-director-224435157.html", "source_name": "Market source", "published_at": "2026-07-08T22:41:16", "published_display": "08 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Larimar Therapeutics Inc For: 8 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOcS0waWZPMU9Xem1lbUk1azlDakRBMEEzYUhFb2loT0tNdHBkMmJBOGlzOXFHXy12RndQd2JJZnhoQXV3UERldHV4U1dpMTludmVOTmlLcHFucXh1Znk2SE93TWRwNnlkamxVRkduVTRmaWU0ZWxQYW5SdlV3Z1ctTmtRY0JIdVZpQmhjb0pQaXdvQ2cyUzZVbjl3emFvMFFBM0VwTWpB?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-08T20:22:11+00:00", "published_display": "08 Jul 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) director purchases 50,000 common shares", "summary": "Larimar Therapeutics director Thomas Edward Hamilton purchased 50,000 common shares in an open-market transaction at a weighted average price of $3.3378 per share. Following this acquisition, Hamilton now directly holds 714,798 common shares and indirectly holds 159,433 shares th", "url": "https://www.stocktitan.net/sec-filings/LRMR/form-4-larimar-therapeutics-inc-insider-trading-activity-e22508a8c313.html", "source_name": "Stock Titan", "published_at": "2026-07-08T19:41:16", "published_display": "08 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Larimar Therapeutics Inc (LRMR)", "summary": "This article analyzes the historical performance of investing $1,000 in Larimar Therapeutics Inc (LRMR) over 1, 5, and 10 years, detailing the returns and compound annual growth rates. It also provides an overview of Larimar Therapeutics, a clinical-stage biotechnology company fo", "url": "https://www.stocktitan.net/tools/stock-return-calculator/LRMR", "source_name": "Stock Titan", "published_at": "2026-07-04T01:40:31", "published_display": "04 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What Citi Thinks About Larimar Therapeutics (LRMR)", "summary": "Citi analyst Samantha Semenkow maintained a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target, citing optimism surrounding its lead drug Nomlabofusp for Friedreich\u2019s ataxia. The bullish outlook is driven by upcoming catalysts including new clinical data and a plan", "url": "https://www.insidermonkey.com/blog/heres-what-citi-thinks-about-larimar-therapeutics-lrmr-1794176/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-03T09:13:00", "published_display": "03 Jul 2026 09:13", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns", "summary": "Shares of Larimar Therapeutics (LRMR) held steady despite recent weakness driven by drug safety concerns, as Wall Street analysts maintained bullish ratings. H.C. Wainwright initiated coverage with a 'Buy' rating and a $10 price target, citing the company's regulatory progress fo", "url": "https://finance.yahoo.com/healthcare/articles/lrmr-shares-hold-steady-wall-203252936.html", "source_name": "Market source", "published_at": "2026-07-02T20:32:00", "published_display": "02 Jul 2026 20:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Larimar Therapeutics, Inc. \u2013 LS:A2P5PP", "summary": "This article provides financial information for Larimar Therapeutics, Inc. under the stock symbol LS:A2P5PP. It specifically highlights the \"Price to book forward\" metric. The content appears to be a financial data page from TradingView, indicating that the market is currently cl", "url": "https://www.tradingview.com/symbols/LS-A2P5PP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T15:39:19", "published_display": "02 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR Assumed by HC Wainwright & Co. -- Rating Set to Buy", "summary": "HC Wainwright & Co. has initiated coverage on Larimar Therapeutics (LRMR) with a Buy rating and a price target of $10.00, citing confidence in the company's potential despite its current low profitability and growth metrics. Larimar Therapeutics, a clinical-stage biotechnology co", "url": "https://www.gurufocus.com/news/8942871/lrmr-assumed-by-hc-wainwright-co-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-07-02T13:12:17", "published_display": "02 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Larimar Therapeutics, Inc. \u2013 NASDAQ:LRMR", "summary": "This page from TradingView displays the \"Price to book forward\" metric for Larimar Therapeutics, Inc. (NASDAQ: LRMR). The content indicates the company's financial overview within the health technology and biotechnology sectors. It also includes general disclaimers about market d", "url": "https://www.tradingview.com/symbols/NASDAQ-LRMR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T11:12:17", "published_display": "02 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Larimar Therapeutics, Inc. \u2013 LS:A2P5PP", "summary": "This article provides access to the enterprise value to EBIT forward data for Larimar Therapeutics, Inc. (LS:A2P5PP) on the TradingView platform. It highlights that the market was closed at the time of access and no trades were recorded. The financial data is provided by ICE Data", "url": "https://www.tradingview.com/symbols/LS-A2P5PP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T07:39:51", "published_display": "01 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR Stock Dips As Traders Weigh Cash Runway And Volatility", "summary": "Larimar Therapeutics Inc. (LRMR) stock fell by 15.16% due to concerns over clinical trial and regulatory updates, closing around $3.11 after an intraday high of $4.30. Despite a strong cash position of $178.5 million, the biotech firm is burning significant cash on R&D, making it", "url": "https://stockstotrade.com/news/larimar-therapeutics-inc-lrmr-news-2026_06_29-2/", "source_name": "StocksToTrade", "published_at": "2026-06-29T18:10:05", "published_display": "29 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar says FDA can review nomlabofusp for accelerated approval", "summary": "Larimar Therapeutics (LRMR) has submitted the first module of a rolling Biologics License Application (BLA) for accelerated FDA approval of nomlabofusp, a treatment for Friedreich\u2019s ataxia. The FDA noted that existing data, including sustained increases in skin frataxin (FXN) lev", "url": "https://www.stocktitan.net/news/LRMR/larimar-therapeutics-reports-positive-open-label-data-and-submission-brxo5xqfktxj.html", "source_name": "Stock Titan", "published_at": "2026-06-29T16:40:52", "published_display": "29 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug", "summary": "Larimar Therapeutics' stock fell by 15% despite the FDA backing a rolling Biologics License Application (BLA) submission for nomlabofusp, its rare disease drug for Friedreich's ataxia. The FDA indicated that existing data appears capable of supporting the BLA and agreed to consid", "url": "https://www.benzinga.com/markets/equities/26/06/60158521/larimar-stock-slides-15-despite-fda-backing-rolling-submission-for-rare-disease-drug", "source_name": "Benzinga", "published_at": "2026-06-29T14:09:14", "published_display": "29 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar's Rare Disease Push Just Hit A Key Inflection Point \u2014 What Investors Need To Know", "summary": "", "url": "https://finance.yahoo.com/m/de2c88a5-b734-3bae-aed5-f64e27f65f8a/larimar%27s-rare-disease-push.html", "source_name": "Stocktwits", "published_at": "2026-06-29T13:02:48+00:00", "published_display": "29 Jun 2026 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/larimar-therapeutics-files-first-module-122659781.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:26:59+00:00", "published_display": "29 Jun 2026 12:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Microcap Growth Benchmark Index", "summary": "Larimar Therapeutics, Inc. (NasdaqGM:LRMR) has been added to the Russell Microcap Growth Benchmark Index. This news follows several other index-related adjustments for the company and other significant corporate updates, including filing the first module of its Biologics License ", "url": "https://www.marketscreener.com/news/larimar-therapeutics-inc-nasdaqgm-lrmr-added-to-russell-microcap-growth-benchmark-index-ce7f5fded089f324", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:43:39", "published_display": "29 Jun 2026 11:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics submits first module of rolling BLA for nomlabofusp in Friedreich\u2019s ataxia", "summary": "Larimar Therapeutics has submitted the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp, a treatment for Friedreich\u2019s ataxia. The company expects to submit the remaining BLA modules in the second half of 2026. Open-l", "url": "https://grafa.com/en/news/united-states/larimar-therapeutics-rolling-bla-nomlabofusp-friedreich-ataxia", "source_name": "grafa.com", "published_at": "2026-06-29T10:53:00", "published_display": "29 Jun 2026 10:53", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics submits first module of rolling BLA after positive nomlabofusp open\u2011label data", "summary": "Larimar Therapeutics has submitted the first module of a rolling Biologics License Application (BLA) for accelerated approval of nomlabofusp, citing positive long-term open-label data. The data indicates sustained increases in skin FXN and clinical improvements. The company antic", "url": "https://www.tradingview.com/news/tradingview:d1266727c3df8:0-larimar-therapeutics-submits-first-module-of-rolling-bla-after-positive-nomlabofusp-open-label-data/", "source_name": "TradingView", "published_at": "2026-06-29T10:43:39", "published_display": "29 Jun 2026 10:43", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia", "summary": "Larimar Therapeutics announced the submission of the first module of its rolling Biologics License Application (BLA) for accelerated approval of nomlabofusp, a treatment for Friedreich\u2019s ataxia. The company also reported positive long-term open-label study data, showing sustained", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318791/0/en/larimar-therapeutics-reports-positive-open-label-data-and-submission-of-first-module-of-rolling-bla-for-accelerated-approval-of-nomlabofusp-for-friedreich-s-ataxia.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T10:43:39", "published_display": "29 Jun 2026 10:43", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR Stock Slides As Traders Eye Cash Runway And Volatility", "summary": "Larimar Therapeutics Inc. (LRMR) stock has dropped by 14.62% due to bearish sentiment surrounding its recent clinical developments. Despite concerns over profitability, the company maintains a strong cash position of approximately $178 million, providing a significant runway for ", "url": "https://stockstotrade.com/news/larimar-therapeutics-inc-lrmr-news-2026_06_29/", "source_name": "StocksToTrade", "published_at": "2026-06-29T10:03:00", "published_display": "29 Jun 2026 10:03", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcmhWWUZLYnN2cUQ5MGtLTTZ1M3daclZkbnpwUFc0UkNGcnYyS3JzUTYwMHowUEFnbm5xMzduQl9DZEMwVnR6Z2xvUlA2LVh2bl8ybThZWTZnYkZ5eWg4Z3NMRHdCb2RyR0oxbzFVaUJMRFNhY01aR2VfRVYtOTlCSXNsLVBFa2lNQllOMzlIZUJjT016RGtBb1hNSnpXR2J5emdYa1lR?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (Nasdaq: LRMR) advances nomlabofusp with rolling BLA and Phase 3 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNbGc3V2xYamVsTC1NaUk5YnhHcG1wbmhPVGZFRmRlM3ZicXRSbXNtcnlVb1pnZnJ4cGUwS1cwWGlnRTVtMFNBZ3pWRGZ4U281NTExc1FLY1VlVXBqcURubGVzQ0g0WlRCQVRxaDd6QXVsVTNwdjFFb1dHdEVEcElBbEtaMVd4dGxnQUM2WlRsbkRNSzBLMjlHLWhqeXByZDhMYmpodzNtdmd3WEFVb0puQjZ0dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics stock tumbles after clinical data release", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOZnRrdHM0azRSRUNqUnBmak13YUQ3blR4VU5ZSHNNU2dLdEpkNFJ4NlJiUk5IdjBxYlV3N3BLQ3hkSzFuRlpnOE9OWS1GSlU0dUtoY2N3c0FKaGdTemdDME5xQU1fQ3VCUHU4TXpsTklqMFFMVFlKU09tWmpkcGFhbmkxV1BHNkloODRCdzVtU0M4emxuQ1o5bjhQTGMwZk1nMnZLUkVEUGI4MGVKWThaWEFFVGJiMzZsRG95QnhhOGtRdw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 2000 Growth Benchmark", "summary": "Larimar Therapeutics, Inc. (NasdaqGM: LRMR) has been added to the Russell 2000 Growth Benchmark index. This inclusion highlights the company's growth trajectory within the biotechnology and medical research sector. The company is focused on developing treatments for rare diseases", "url": "https://www.marketscreener.com/news/larimar-therapeutics-inc-nasdaqgm-lrmr-added-to-russell-2000-growth-benchmark-ce7f5fdede80f025", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:01:00", "published_display": "29 Jun 2026 07:01", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia", "summary": "Larimar Therapeutics is hosting an investor event to discuss updates on its nomlabofusp program for Friedreich's Ataxia. This event will provide insights into the progress and future plans for this therapeutic candidate. Investors will have the opportunity to learn more about the", "url": "https://www.moomoo.com/news/post/72125500/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for", "source_name": "Moomoo", "published_at": "2026-06-27T02:10:36", "published_display": "27 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics to host investor event on Monday By Investing.com", "summary": "Larimar Therapeutics (NASDAQ:LRMR) is hosting an investor event on Monday, June 29, 2026, to discuss updates on its nomlabofusp clinical development program for Friedreich's ataxia, including regulatory information and long-term study data. The clinical-stage biotech company, wit", "url": "https://m.au.investing.com/news/stock-market-news/larimar-therapeutics-to-host-investor-event-on-monday-93CH-4507257?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-27T01:39:15", "published_display": "27 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFB4Y3hrbTkzODRfOWwyN1R0eTdRUF9KZUJkdUQtZHpDNHc2bVQwLWg1WGZ4QWR1R3lobWRyUDNGVGNucmpzYmgyMFdrNERnakpXTnVQTk1WRUtYajA?oc=5", "source_name": "ChartMill", "published_at": "2026-06-26T20:31:57+00:00", "published_display": "26 Jun 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/larimar-therapeutics-announces-investor-event-200500879.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T20:05:00+00:00", "published_display": "26 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) entity tied to director receives 55,150 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSHRGMWJoNFBXRjhWRW5mczB5TVVUeGFXb3hjeTBEMDJGbDBMLTB4eEhtMVExdWtVeGV3b1FYbjZIMEpWcEtLcGNTdDVEcTBxMDdreVIwOHF3VjBURnJNSlRIaVhKcE9wUms0S1FCd0FZVzBGN0RNbE1XQ2dBTDlEb2djNTlTSU1yY2tqb2ltOEJhd2hDNmFQZTRKdEhrWWpiYmw4QzBDNGVzRUdPWm5uNGMzc0t5U0QzdGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) awards 55,150 stock options to director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQc0Nfd19RVzhERHpINEFvY1BTSEM3UUdaZC1WYktRYlBjbFZOMnA1ek9hczFLbFZ4ZFR1U1N3SHRuQy1mSDVUTFNsQ3BlaUVjbHN5MW5SVV9yMGw2ZFhBT2NzMjIwOEM2MFZrS3h6V1ZQNDlIcDlTUHB1ZHZtU191MFFQWTllSm1iOFNwM05uZjNNNThmWmhQVDZoTU52Z19wWXREMDZVOU1NZ080SmJrZDREUmlvZGVtMEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Blue Owl (NASDAQ: LRMR) discloses 9.99% position totaling 10.74M shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNS1EyN0JZQVAxQlExNHJwcEwtS1kzcW9xdWhUTDdvRkJRd1N1TGxyUldCVUlUY28tQ2lYa2FaaDctSkRNYzAzck55czZfMnUwbE93UFJCYlo1V0VIVWRNQ1hiaU9KdWVVS0hXVWIyMGtYX1d3TjhtMnhQS0FaVnlxQzQzWDFvWmI4eGhIUXgySXZYV3JTTy02YmYwU1pHTTZnVjJFVUZTdU1wU241bUk2bEU1Z1lEYVpTNDh4Z3VjZ0trWHNGaXI0enFIOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPejgtNGtPZ2Y2cUNWRFR1cFRxd0xrbzV2eUdjaW8yOXBmaTU0WGFkRTFoc29RdC1PM1FpWDBlblJQQkZiVEtxU3BySDZwY0s0elMzUktSM3J3NWVrZG5vUHpJWW11c2l4ajlpYWpZMXBscVpIaEllTmVOV1M1WVhDbUE2MUhETmZ0cEJKMmVhOF9mWEhuZHJfSXc5akNjaFVHX1BZc3p5V0hEaVllRTJ5eS1ZUFktaWJKenhRSFcxQ1k3S3htZ0w5enlrdmtmNHNWMjB0T3ppcFRQTXlvWnJYb1V6SQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNRnc0TUkwREpTemtaajMtaGRvbHlGQlFJWWFJNXBTSXZjVjBsYjR1dERuSUIzLTVoZVJrV3hESVlXTjhuNnMtMHNSWmJfWXhUTzNMSS1ZNkx3S2NjV21CZGdpYU52aUVLSHJ0SXpmbEl3NU5xN1BVVmtyZEZucnR2MU5PNGp3RUdMcnBMTjZiVGNoV0RkbDZCSDVaeUdVVnN6OUE?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQS2hsQ3BTR3VHbVRFYmRJYVZURmtaeFhEZjN6dERWVlR6N3B3Z19reEZubTlsWXRxLUpKQW9EQTg5eVptWVRDYU03X1UwNmpseTgyYmxSMXYxMDNwcU1OYXVjQmlZZVI5ODZMNkJVcm9zWnFCR1FDZUhZYjVvakZCTll3cThTN3JWdTI2QTM2NDFrUkVCWVJZN21mUlV4S1ZNRjlKQzE5cHAtSlBmNTlPMTZTSVR3dE0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPSDVrZXY1X0FldmtPRkxXcmVhUUpNZHVQSzV1aExaSG1xSzZUYWJqOTlENHBhTnlmVUhrUUZSam1FaFBkMzFGMzE4VVV5LWR5OHZUYU5TWGIyVEJwZUZpSV9DRzJob3E5X0VRTWZVUEJ2U0FDSUYzd1FZOVlSWnZPaHdR?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) Is Up 85.9% After Breakthrough Status For Nomlabofusp In Friedreich\u2019s Ataxia", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) Valuation After FDA Breakthrough Therapy Designation For Nomlabofusp", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQeXB5cEQ2OU9EWnZpZFFOX3V6ejA3dmRudGducTJlM3Z3cjYxVVR5N3JMS0hRQlZWQkUzcjhRcm1XeHVfWHpPdFNSLUxhTEJ3THRRa01veFRMN0g4YTFsbGU2OVQxTnFUYWlVLVkybXpLUUItQnpMUWw5SldaUzRiaWtJMnB0dWxTVFJ1V3dSWVplLVdYNW54czlMT2txOHhwaWYyVDhjV3dwbUlwWS1xZDlGWVJlSE9JTmQ2M056a2VpazdFdUF3RFdheWItdVJtQUd1UW1XNUZhMm1ibUFvWm51SlhJZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQTZURGttajhWT1k3WW1Ub1NFeDBPV2xZQWd4SmFwR0oxZXhjWDRNUE94b0ZGY1doTDVzTFNRZFRMTjhqanBSMnVMVDdDYzgtdUVqS1NHWEx3Mm9SdDYxemFhUE1NS1Vkcng1b01RMWJpaG92ZjJsd3ZvejFoY2QzSVRXVmh3RnZhM1d1RlFBNGFoRWRpRG9RTEMwU09yTjdsbGpJb2p6S2RpZU0?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-24T18:43:17+00:00", "published_display": "24 Feb 2026 18:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Stock Surges Following Impressive Financial Indicators", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQcHFYOE1GalY3WFR0WUtXQWFYTFRGbmM4UzRSTHFvODFxaFkzUEsxSzRIOUFrVW9DRVBkWTJiOEk5UHNZZDF0b3VtYVBZWHRHTnY2OWhwX3NOY2Z3MzdxTl9WcW96YzExYnZkQWhoWnF0VHd0NkpBX0p1YlR6Z3J3V1liQQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOX0FkMkh1d21fYTJUb3oyQWNHSG9IdkxpY2tsZjQ3bWw1MlBkT2NFSkZpRVNnbnhBeXNGdGJ5TFRIR05sUkhRU29TZWRzUHlKSkFzaGxtT19hb2p4dTdHeXpHQWxXMUlQSlUwbDdjd2Z4TnA3TzhLanhqTDAtYmU0OHpNbw?oc=5", "source_name": "Market source", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy", "summary": "Larimar Therapeutics (LRMR) has submitted the initial module of its Biologics License Application (BLA) to the U.S. FDA for accelerated approval of its Nomlabofusp therapy, targeting Friedreich's ataxia. The therapy showed positive results in an open-label study, and the FDA conf", "url": "https://finance.yahoo.com/healthcare/articles/larimar-therapeutics-lrmr-submits-initial-154308058.html", "source_name": "Market source", "published_at": "2026-07-15T10:43:00", "published_display": "15 Jul 2026 10:43", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR | FinancialContent", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) on behalf of investors. The investigation stems from two instances where the company's stock price fell significantly after announcing \"positive\" data from a Friedre", "url": "https://www.financialcontent.com/article/gnwcq-2026-7-14-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-larimar-therapeutics-inc-lrmr", "source_name": "FinancialContent", "published_at": "2026-07-14T21:15:25", "published_display": "14 Jul 2026 21:15", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Larimar Therapeutics\u2019 Stock Surge Over 30% Pre-Market Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQQmU4N2hWTlEwb1lUSHJfeXlnOFlDbkRyWUNyZWxPT29QX3Z0NUl0eTE4UGJTZGEtM3U5dEhYeGNNRFVwMHROZm1CdzhVenJlRDA1OFNnTHozaThIWVZ1ejlsQzdLOUhHSXpiT2VCR1FDM2d0VDZLd0c3WjZRcDM0RGgwVGhkNWczem9Fb2F4N1Z6bmh3Tjc3a1Qtd1A5MEk3R21YMWxocmdLR2FSdEpRelZpRzEyREhTNUNTVVpR?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T03:50:05+00:00", "published_display": "14 Jul 2026 03:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Larimar Therapeutics, Inc. \u2013 LS:A2P5PP", "summary": "This article displays the \"Price to earnings forward\" for Larimar Therapeutics, Inc. (A2P5PP) on the TradingView platform. It shows that the market for this stock is closed and there have been no trades for this specific financial metric. The content primarily focuses on the disp", "url": "https://www.tradingview.com/symbols/LS-A2P5PP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T01:10:54", "published_display": "14 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy", "summary": "Larimar Therapeutics Inc. (LRMR) has priced an upsized $100 million stock offering after its shares surged over 60% following the FDA granting Breakthrough Therapy Designation to its frataxin protein replacement therapy, Nomlabofusp, for Friedreich\u2019s ataxia. The funds will suppor", "url": "https://stocktwits.com/news-articles/markets/equity/larimar-prices-100-m-stock-sale-after-record-rally-fueled-by-fda-breakthrough-tag-for-protein-replacement-therapy/cZR6UicRIbc", "source_name": "Stocktwits", "published_at": "2026-07-13T19:42:05", "published_display": "13 Jul 2026 19:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Larimar Therapeutics, Inc. \u2013 NASDAQ:LRMR", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNcUU0UDY1RVRKd0lydnd2bGQ0OHl4amhBWkRZRDhPWHc0V0wzbHR5WnRhNDZucGNTS2pDVnNxU2s3bzByM0paQV93dUtJUE12V3otN19TQjQ2eFB0cEpQNXlKck9jNmtFMHF4bzdFTFI0YWhqNXg0ZkNENlpYNnhiU0tmZUcyTmpTb1dKQ1lBc25NbDVWRi11ZXl0Z21VZw?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T15:47:04+00:00", "published_display": "12 Jul 2026 15:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Thomas Hamilton Bought 6.1% More Shares In Larimar Therapeutics", "summary": "The article reports that Thomas Hamilton increased his holdings in Larimar Therapeutics by 6.1%. This acquisition suggests a positive outlook on the company's future prospects from a notable investor.", "url": "https://www.moomoo.com/news/post/72780626/thomas-hamilton-bought-6-1-more-shares-in-larimar-therapeutics", "source_name": "Moomoo", "published_at": "2026-07-10T18:09:42", "published_display": "10 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR", "summary": "Pomerantz LLP is investigating claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows two significant stock price drops after the company disclosed instances of anap", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-larimar-therapeutics-inc---lrmr-302822376.html", "source_name": "PR Newswire", "published_at": "2026-07-09T19:57:00", "published_display": "09 Jul 2026 19:57", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics stock jumps on insider purchase By Investing.com", "summary": "Larimar Therapeutics Inc (NASDAQ:LRMR) shares jumped 15.5% after director Thomas Edward Hamilton purchased 50,000 shares of common stock. The insider acquisition, valued at approximately $166,890, signals confidence in the biopharmaceutical company from a board member. Hamilton n", "url": "https://in.investing.com/news/stock-market-news/larimar-therapeutics-stock-jumps-on-insider-purchase-93CH-5490015", "source_name": "Investing.com India", "published_at": "2026-07-09T16:10:21", "published_display": "09 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Larimar Therapeutics, Inc. \u2013 SWB:ZA71", "summary": "This article provides financial information for Larimar Therapeutics, Inc. (SWB:ZA71) available on TradingView, specifically focusing on its enterprise value to revenue forward. It indicates the stock is traded on the Stuttgart Stock Exchange and details various financial and res", "url": "https://www.tradingview.com/symbols/SWB-ZA71/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T23:41:16", "published_display": "08 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000", "summary": "Shares of Larimar Therapeutics, Inc. (LRMR) rose 3% after hours following director Thomas E. Hamilton's purchase of 50,000 shares for approximately $167,000. This insider buying comes as H.C. Wainwright initiated 'Buy' coverage with a $10 price target, anticipating a commercial l", "url": "https://finance.yahoo.com/markets/stocks/articles/lrmr-stock-edges-hours-director-224435157.html", "source_name": "Market source", "published_at": "2026-07-08T22:41:16", "published_display": "08 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Larimar Therapeutics Inc For: 8 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOcS0waWZPMU9Xem1lbUk1azlDakRBMEEzYUhFb2loT0tNdHBkMmJBOGlzOXFHXy12RndQd2JJZnhoQXV3UERldHV4U1dpMTludmVOTmlLcHFucXh1Znk2SE93TWRwNnlkamxVRkduVTRmaWU0ZWxQYW5SdlV3Z1ctTmtRY0JIdVZpQmhjb0pQaXdvQ2cyUzZVbjl3emFvMFFBM0VwTWpB?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-08T20:22:11+00:00", "published_display": "08 Jul 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) director purchases 50,000 common shares", "summary": "Larimar Therapeutics director Thomas Edward Hamilton purchased 50,000 common shares in an open-market transaction at a weighted average price of $3.3378 per share. Following this acquisition, Hamilton now directly holds 714,798 common shares and indirectly holds 159,433 shares th", "url": "https://www.stocktitan.net/sec-filings/LRMR/form-4-larimar-therapeutics-inc-insider-trading-activity-e22508a8c313.html", "source_name": "Stock Titan", "published_at": "2026-07-08T19:41:16", "published_display": "08 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Larimar Therapeutics Inc (LRMR)", "summary": "This article analyzes the historical performance of investing $1,000 in Larimar Therapeutics Inc (LRMR) over 1, 5, and 10 years, detailing the returns and compound annual growth rates. It also provides an overview of Larimar Therapeutics, a clinical-stage biotechnology company fo", "url": "https://www.stocktitan.net/tools/stock-return-calculator/LRMR", "source_name": "Stock Titan", "published_at": "2026-07-04T01:40:31", "published_display": "04 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What Citi Thinks About Larimar Therapeutics (LRMR)", "summary": "Citi analyst Samantha Semenkow maintained a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target, citing optimism surrounding its lead drug Nomlabofusp for Friedreich\u2019s ataxia. The bullish outlook is driven by upcoming catalysts including new clinical data and a plan", "url": "https://www.insidermonkey.com/blog/heres-what-citi-thinks-about-larimar-therapeutics-lrmr-1794176/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-03T09:13:00", "published_display": "03 Jul 2026 09:13", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns", "summary": "Shares of Larimar Therapeutics (LRMR) held steady despite recent weakness driven by drug safety concerns, as Wall Street analysts maintained bullish ratings. H.C. Wainwright initiated coverage with a 'Buy' rating and a $10 price target, citing the company's regulatory progress fo", "url": "https://finance.yahoo.com/healthcare/articles/lrmr-shares-hold-steady-wall-203252936.html", "source_name": "Market source", "published_at": "2026-07-02T20:32:00", "published_display": "02 Jul 2026 20:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Larimar Therapeutics, Inc. \u2013 LS:A2P5PP", "summary": "This article provides financial information for Larimar Therapeutics, Inc. under the stock symbol LS:A2P5PP. It specifically highlights the \"Price to book forward\" metric. The content appears to be a financial data page from TradingView, indicating that the market is currently cl", "url": "https://www.tradingview.com/symbols/LS-A2P5PP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T15:39:19", "published_display": "02 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR Assumed by HC Wainwright & Co. -- Rating Set to Buy", "summary": "HC Wainwright & Co. has initiated coverage on Larimar Therapeutics (LRMR) with a Buy rating and a price target of $10.00, citing confidence in the company's potential despite its current low profitability and growth metrics. Larimar Therapeutics, a clinical-stage biotechnology co", "url": "https://www.gurufocus.com/news/8942871/lrmr-assumed-by-hc-wainwright-co-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-07-02T13:12:17", "published_display": "02 Jul 2026 13:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Larimar Therapeutics, Inc. \u2013 NASDAQ:LRMR", "summary": "This page from TradingView displays the \"Price to book forward\" metric for Larimar Therapeutics, Inc. (NASDAQ: LRMR). The content indicates the company's financial overview within the health technology and biotechnology sectors. It also includes general disclaimers about market d", "url": "https://www.tradingview.com/symbols/NASDAQ-LRMR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T11:12:17", "published_display": "02 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Larimar Therapeutics, Inc. \u2013 LS:A2P5PP", "summary": "This article provides access to the enterprise value to EBIT forward data for Larimar Therapeutics, Inc. (LS:A2P5PP) on the TradingView platform. It highlights that the market was closed at the time of access and no trades were recorded. The financial data is provided by ICE Data", "url": "https://www.tradingview.com/symbols/LS-A2P5PP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T07:39:51", "published_display": "01 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR Stock Dips As Traders Weigh Cash Runway And Volatility", "summary": "Larimar Therapeutics Inc. (LRMR) stock fell by 15.16% due to concerns over clinical trial and regulatory updates, closing around $3.11 after an intraday high of $4.30. Despite a strong cash position of $178.5 million, the biotech firm is burning significant cash on R&D, making it", "url": "https://stockstotrade.com/news/larimar-therapeutics-inc-lrmr-news-2026_06_29-2/", "source_name": "StocksToTrade", "published_at": "2026-06-29T18:10:05", "published_display": "29 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar says FDA can review nomlabofusp for accelerated approval", "summary": "Larimar Therapeutics (LRMR) has submitted the first module of a rolling Biologics License Application (BLA) for accelerated FDA approval of nomlabofusp, a treatment for Friedreich\u2019s ataxia. The FDA noted that existing data, including sustained increases in skin frataxin (FXN) lev", "url": "https://www.stocktitan.net/news/LRMR/larimar-therapeutics-reports-positive-open-label-data-and-submission-brxo5xqfktxj.html", "source_name": "Stock Titan", "published_at": "2026-06-29T16:40:52", "published_display": "29 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug", "summary": "Larimar Therapeutics' stock fell by 15% despite the FDA backing a rolling Biologics License Application (BLA) submission for nomlabofusp, its rare disease drug for Friedreich's ataxia. The FDA indicated that existing data appears capable of supporting the BLA and agreed to consid", "url": "https://www.benzinga.com/markets/equities/26/06/60158521/larimar-stock-slides-15-despite-fda-backing-rolling-submission-for-rare-disease-drug", "source_name": "Benzinga", "published_at": "2026-06-29T14:09:14", "published_display": "29 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar's Rare Disease Push Just Hit A Key Inflection Point \u2014 What Investors Need To Know", "summary": "", "url": "https://finance.yahoo.com/m/de2c88a5-b734-3bae-aed5-f64e27f65f8a/larimar%27s-rare-disease-push.html", "source_name": "Stocktwits", "published_at": "2026-06-29T13:02:48+00:00", "published_display": "29 Jun 2026 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/larimar-therapeutics-files-first-module-122659781.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:26:59+00:00", "published_display": "29 Jun 2026 12:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Microcap Growth Benchmark Index", "summary": "Larimar Therapeutics, Inc. (NasdaqGM:LRMR) has been added to the Russell Microcap Growth Benchmark Index. This news follows several other index-related adjustments for the company and other significant corporate updates, including filing the first module of its Biologics License ", "url": "https://www.marketscreener.com/news/larimar-therapeutics-inc-nasdaqgm-lrmr-added-to-russell-microcap-growth-benchmark-index-ce7f5fded089f324", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:43:39", "published_display": "29 Jun 2026 11:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics submits first module of rolling BLA for nomlabofusp in Friedreich\u2019s ataxia", "summary": "Larimar Therapeutics has submitted the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp, a treatment for Friedreich\u2019s ataxia. The company expects to submit the remaining BLA modules in the second half of 2026. Open-l", "url": "https://grafa.com/en/news/united-states/larimar-therapeutics-rolling-bla-nomlabofusp-friedreich-ataxia", "source_name": "grafa.com", "published_at": "2026-06-29T10:53:00", "published_display": "29 Jun 2026 10:53", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics submits first module of rolling BLA after positive nomlabofusp open\u2011label data", "summary": "Larimar Therapeutics has submitted the first module of a rolling Biologics License Application (BLA) for accelerated approval of nomlabofusp, citing positive long-term open-label data. The data indicates sustained increases in skin FXN and clinical improvements. The company antic", "url": "https://www.tradingview.com/news/tradingview:d1266727c3df8:0-larimar-therapeutics-submits-first-module-of-rolling-bla-after-positive-nomlabofusp-open-label-data/", "source_name": "TradingView", "published_at": "2026-06-29T10:43:39", "published_display": "29 Jun 2026 10:43", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia", "summary": "Larimar Therapeutics announced the submission of the first module of its rolling Biologics License Application (BLA) for accelerated approval of nomlabofusp, a treatment for Friedreich\u2019s ataxia. The company also reported positive long-term open-label study data, showing sustained", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318791/0/en/larimar-therapeutics-reports-positive-open-label-data-and-submission-of-first-module-of-rolling-bla-for-accelerated-approval-of-nomlabofusp-for-friedreich-s-ataxia.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T10:43:39", "published_display": "29 Jun 2026 10:43", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR Stock Slides As Traders Eye Cash Runway And Volatility", "summary": "Larimar Therapeutics Inc. (LRMR) stock has dropped by 14.62% due to bearish sentiment surrounding its recent clinical developments. Despite concerns over profitability, the company maintains a strong cash position of approximately $178 million, providing a significant runway for ", "url": "https://stockstotrade.com/news/larimar-therapeutics-inc-lrmr-news-2026_06_29/", "source_name": "StocksToTrade", "published_at": "2026-06-29T10:03:00", "published_display": "29 Jun 2026 10:03", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcmhWWUZLYnN2cUQ5MGtLTTZ1M3daclZkbnpwUFc0UkNGcnYyS3JzUTYwMHowUEFnbm5xMzduQl9DZEMwVnR6Z2xvUlA2LVh2bl8ybThZWTZnYkZ5eWg4Z3NMRHdCb2RyR0oxbzFVaUJMRFNhY01aR2VfRVYtOTlCSXNsLVBFa2lNQllOMzlIZUJjT016RGtBb1hNSnpXR2J5emdYa1lR?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (Nasdaq: LRMR) advances nomlabofusp with rolling BLA and Phase 3 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNbGc3V2xYamVsTC1NaUk5YnhHcG1wbmhPVGZFRmRlM3ZicXRSbXNtcnlVb1pnZnJ4cGUwS1cwWGlnRTVtMFNBZ3pWRGZ4U281NTExc1FLY1VlVXBqcURubGVzQ0g0WlRCQVRxaDd6QXVsVTNwdjFFb1dHdEVEcElBbEtaMVd4dGxnQUM2WlRsbkRNSzBLMjlHLWhqeXByZDhMYmpodzNtdmd3WEFVb0puQjZ0dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics stock tumbles after clinical data release", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOZnRrdHM0azRSRUNqUnBmak13YUQ3blR4VU5ZSHNNU2dLdEpkNFJ4NlJiUk5IdjBxYlV3N3BLQ3hkSzFuRlpnOE9OWS1GSlU0dUtoY2N3c0FKaGdTemdDME5xQU1fQ3VCUHU4TXpsTklqMFFMVFlKU09tWmpkcGFhbmkxV1BHNkloODRCdzVtU0M4emxuQ1o5bjhQTGMwZk1nMnZLUkVEUGI4MGVKWThaWEFFVGJiMzZsRG95QnhhOGtRdw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 2000 Growth Benchmark", "summary": "Larimar Therapeutics, Inc. (NasdaqGM: LRMR) has been added to the Russell 2000 Growth Benchmark index. This inclusion highlights the company's growth trajectory within the biotechnology and medical research sector. The company is focused on developing treatments for rare diseases", "url": "https://www.marketscreener.com/news/larimar-therapeutics-inc-nasdaqgm-lrmr-added-to-russell-2000-growth-benchmark-ce7f5fdede80f025", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:01:00", "published_display": "29 Jun 2026 07:01", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia", "summary": "Larimar Therapeutics is hosting an investor event to discuss updates on its nomlabofusp program for Friedreich's Ataxia. This event will provide insights into the progress and future plans for this therapeutic candidate. Investors will have the opportunity to learn more about the", "url": "https://www.moomoo.com/news/post/72125500/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for", "source_name": "Moomoo", "published_at": "2026-06-27T02:10:36", "published_display": "27 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics to host investor event on Monday By Investing.com", "summary": "Larimar Therapeutics (NASDAQ:LRMR) is hosting an investor event on Monday, June 29, 2026, to discuss updates on its nomlabofusp clinical development program for Friedreich's ataxia, including regulatory information and long-term study data. The clinical-stage biotech company, wit", "url": "https://m.au.investing.com/news/stock-market-news/larimar-therapeutics-to-host-investor-event-on-monday-93CH-4507257?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-27T01:39:15", "published_display": "27 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFB4Y3hrbTkzODRfOWwyN1R0eTdRUF9KZUJkdUQtZHpDNHc2bVQwLWg1WGZ4QWR1R3lobWRyUDNGVGNucmpzYmgyMFdrNERnakpXTnVQTk1WRUtYajA?oc=5", "source_name": "ChartMill", "published_at": "2026-06-26T20:31:57+00:00", "published_display": "26 Jun 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich\u2019s Ataxia", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/larimar-therapeutics-announces-investor-event-200500879.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T20:05:00+00:00", "published_display": "26 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) entity tied to director receives 55,150 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSHRGMWJoNFBXRjhWRW5mczB5TVVUeGFXb3hjeTBEMDJGbDBMLTB4eEhtMVExdWtVeGV3b1FYbjZIMEpWcEtLcGNTdDVEcTBxMDdreVIwOHF3VjBURnJNSlRIaVhKcE9wUms0S1FCd0FZVzBGN0RNbE1XQ2dBTDlEb2djNTlTSU1yY2tqb2ltOEJhd2hDNmFQZTRKdEhrWWpiYmw4QzBDNGVzRUdPWm5uNGMzc0t5U0QzdGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) awards 55,150 stock options to director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQc0Nfd19RVzhERHpINEFvY1BTSEM3UUdaZC1WYktRYlBjbFZOMnA1ek9hczFLbFZ4ZFR1U1N3SHRuQy1mSDVUTFNsQ3BlaUVjbHN5MW5SVV9yMGw2ZFhBT2NzMjIwOEM2MFZrS3h6V1ZQNDlIcDlTUHB1ZHZtU191MFFQWTllSm1iOFNwM05uZjNNNThmWmhQVDZoTU52Z19wWXREMDZVOU1NZ080SmJrZDREUmlvZGVtMEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Blue Owl (NASDAQ: LRMR) discloses 9.99% position totaling 10.74M shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNS1EyN0JZQVAxQlExNHJwcEwtS1kzcW9xdWhUTDdvRkJRd1N1TGxyUldCVUlUY28tQ2lYa2FaaDctSkRNYzAzck55czZfMnUwbE93UFJCYlo1V0VIVWRNQ1hiaU9KdWVVS0hXVWIyMGtYX1d3TjhtMnhQS0FaVnlxQzQzWDFvWmI4eGhIUXgySXZYV3JTTy02YmYwU1pHTTZnVjJFVUZTdU1wU241bUk2bEU1Z1lEYVpTNDh4Z3VjZ0trWHNGaXI0enFIOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPejgtNGtPZ2Y2cUNWRFR1cFRxd0xrbzV2eUdjaW8yOXBmaTU0WGFkRTFoc29RdC1PM1FpWDBlblJQQkZiVEtxU3BySDZwY0s0elMzUktSM3J3NWVrZG5vUHpJWW11c2l4ajlpYWpZMXBscVpIaEllTmVOV1M1WVhDbUE2MUhETmZ0cEJKMmVhOF9mWEhuZHJfSXc5akNjaFVHX1BZc3p5V0hEaVllRTJ5eS1ZUFktaWJKenhRSFcxQ1k3S3htZ0w5enlrdmtmNHNWMjB0T3ppcFRQTXlvWnJYb1V6SQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNRnc0TUkwREpTemtaajMtaGRvbHlGQlFJWWFJNXBTSXZjVjBsYjR1dERuSUIzLTVoZVJrV3hESVlXTjhuNnMtMHNSWmJfWXhUTzNMSS1ZNkx3S2NjV21CZGdpYU52aUVLSHJ0SXpmbEl3NU5xN1BVVmtyZEZucnR2MU5PNGp3RUdMcnBMTjZiVGNoV0RkbDZCSDVaeUdVVnN6OUE?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQS2hsQ3BTR3VHbVRFYmRJYVZURmtaeFhEZjN6dERWVlR6N3B3Z19reEZubTlsWXRxLUpKQW9EQTg5eVptWVRDYU03X1UwNmpseTgyYmxSMXYxMDNwcU1OYXVjQmlZZVI5ODZMNkJVcm9zWnFCR1FDZUhZYjVvakZCTll3cThTN3JWdTI2QTM2NDFrUkVCWVJZN21mUlV4S1ZNRjlKQzE5cHAtSlBmNTlPMTZTSVR3dE0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPSDVrZXY1X0FldmtPRkxXcmVhUUpNZHVQSzV1aExaSG1xSzZUYWJqOTlENHBhTnlmVUhrUUZSam1FaFBkMzFGMzE4VVV5LWR5OHZUYU5TWGIyVEJwZUZpSV9DRzJob3E5X0VRTWZVUEJ2U0FDSUYzd1FZOVlSWnZPaHdR?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) Is Up 85.9% After Breakthrough Status For Nomlabofusp In Friedreich\u2019s Ataxia", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics (LRMR) Valuation After FDA Breakthrough Therapy Designation For Nomlabofusp", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQeXB5cEQ2OU9EWnZpZFFOX3V6ejA3dmRudGducTJlM3Z3cjYxVVR5N3JMS0hRQlZWQkUzcjhRcm1XeHVfWHpPdFNSLUxhTEJ3THRRa01veFRMN0g4YTFsbGU2OVQxTnFUYWlVLVkybXpLUUItQnpMUWw5SldaUzRiaWtJMnB0dWxTVFJ1V3dSWVplLVdYNW54czlMT2txOHhwaWYyVDhjV3dwbUlwWS1xZDlGWVJlSE9JTmQ2M056a2VpazdFdUF3RFdheWItdVJtQUd1UW1XNUZhMm1ibUFvWm51SlhJZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQTZURGttajhWT1k3WW1Ub1NFeDBPV2xZQWd4SmFwR0oxZXhjWDRNUE94b0ZGY1doTDVzTFNRZFRMTjhqanBSMnVMVDdDYzgtdUVqS1NHWEx3Mm9SdDYxemFhUE1NS1Vkcng1b01RMWJpaG92ZjJsd3ZvejFoY2QzSVRXVmh3RnZhM1d1RlFBNGFoRWRpRG9RTEMwU09yTjdsbGpJb2p6S2RpZU0?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-24T18:43:17+00:00", "published_display": "24 Feb 2026 18:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Larimar Therapeutics Stock Surges Following Impressive Financial Indicators", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQcHFYOE1GalY3WFR0WUtXQWFYTFRGbmM4UzRSTHFvODFxaFkzUEsxSzRIOUFrVW9DRVBkWTJiOEk5UHNZZDF0b3VtYVBZWHRHTnY2OWhwX3NOY2Z3MzdxTl9WcW96YzExYnZkQWhoWnF0VHd0NkpBX0p1YlR6Z3J3V1liQQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOX0FkMkh1d21fYTJUb3oyQWNHSG9IdkxpY2tsZjQ3bWw1MlBkT2NFSkZpRVNnbnhBeXNGdGJ5TFRIR05sUkhRU29TZWRzUHlKSkFzaGxtT19hb2p4dTdHeXpHQWxXMUlQSlUwbDdjd2Z4TnA3TzhLanhqTDAtYmU0OHpNbw?oc=5", "source_name": "Market source", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 61, "sentiment_summary": {"positive": 20, "negative": 6, "neutral": 35, "score": 56, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.4, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 20, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 4.28, "latest_week": "2026-07-10", "one_week_move": 31.3, "four_week_move": 23.3, "twelve_week_move": -10.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.385936, "market_dynamics_buy_signal": false, "relative_strength": -6.645559, "fair_value_gap": -12.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.3428, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+31.3% over one week, +23.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "TradingView", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "Stocktwits", "count": 3}, {"label": "StocksToTrade", "count": 3}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 12}, {"label": "Regulatory and legal", "count": 8}, {"label": "Analyst action", "count": 5}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+31.3% over one week, +23.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy"}], "updated_at": "2026-07-18T05:50:52.677209+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}